GEORGE FERRY to Antibodies, Monoclonal
This is a "connection" page, showing publications GEORGE FERRY has written about Antibodies, Monoclonal.
Connection Strength
0.163
-
Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin. 2011 Mar; 27(3):651-62.
Score: 0.039
-
Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr. 2009 Aug; 49(2):183-90.
Score: 0.035
-
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007 Mar; 132(3):863-73; quiz 1165-6.
Score: 0.029
-
Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis. 2005 May; 11(5):442-6.
Score: 0.026
-
CDP571, a humanized anti-tumor necrosis factor-alpha monoclonal antibody in pediatric Crohn's disease. Inflamm Bowel Dis. 2004 Nov; 10(6):723-30.
Score: 0.025
-
Clinical challenges and images in GI. Aortitis as a rare complication of Crohn's disease. Gastroenterology. 2008 Mar; 134(3):668, 898.
Score: 0.008